8-K: Traws Pharma Announces Positive Preclinical Results for Tivoxavir Marboxil in Bird Flu Treatment

Traws Pharma reports positive topline data from a preclinical study showing its antiviral candidate, tivoxavir marboxil, effectively suppressed disease in ferrets infected with H5N1 bird flu.

Summary

• Traws Pharma announced positive results from a preclinical study of tivoxavir marboxil as a single-dose treatment for H5N1 avian influenza.
• The study, conducted on ferrets infected with bird flu, showed that tivoxavir marboxil suppressed the disease and reduced viral burden in the lungs.
• These results are consistent with previous findings in a murine model.
• Traws Pharma is also conducting a similar study in non-human primates, with data expected in Q1 2025.
• The company plans to approach the FDA to discuss accelerated approval under the Animal Rule.
• A Virtual Investor Update is scheduled for March 31, 2025, to provide a detailed review of the bird flu program.

Sentiment

Score: 8

Explanation: The announcement of positive preclinical data is a significant positive development for Traws Pharma, increasing the likelihood of future regulatory approval and market success. The company's plan to seek accelerated approval further boosts investor confidence.

Positives

• Tivoxavir marboxil showed positive results in reducing viral burden and improving survival rates in ferrets infected with H5N1 bird flu.
• The results are consistent with previous data from a murine model.
• The company is planning to discuss accelerated approval with the FDA, potentially expediting the drug's availability.
• Tivoxavir marboxil targets the influenza cap-dependent endonuclease (CEN), a highly conserved influenza protein.
• Ratutrelvir is in development as a COVID treatment, targeting the Mpro (3CL protease), without the need for co-administration of ritonavir.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the success and timing of clinical trials, market conditions, and regulatory requirements.
• The extent of the spread and threat of bird flu could impact the potential market for tivoxavir marboxil.
• The potential effectiveness of tivoxavir marboxil for treatment in humans is not yet fully established.

Future Outlook

Traws Pharma intends to approach the FDA to discuss an accelerated approval pathway for tivoxavir marboxil under the Animal Rule, pending the results of the non-human primate study.

Management Comments

• C. David Pauza, PhD, Chief Science Officer, stated that the ferret model testing shows that tivoxavir marboxil has the potential to inhibit disease after bird flu infection.
• Robert R. Redfield, MD, Chief Medical Officer, emphasized the increasing risk of bird flu spread in the human population and the need for effective antiviral drugs.
• Werner Cautreels, Chief Executive Officer, stated the company's intention to approach the FDA to discuss an accelerated approval under the Animal Rule.

Industry Context

The announcement comes amid increasing concerns about the spread of bird flu in animals and the potential for human transmission, highlighting the need for effective medical countermeasures.

Comparison to Industry Standards

• The Animal Rule pathway is often used for products where human efficacy studies are not feasible or ethical, such as in the case of highly pathogenic diseases like bird flu.
• Other companies developing influenza antivirals include Roche (Tamiflu) and Shionogi (Xofluza), which have established products in the seasonal influenza market.
• Traws Pharma's approach of targeting the cap-dependent endonuclease (CEN) is a different mechanism of action compared to neuraminidase inhibitors like Tamiflu, potentially offering an alternative treatment option.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of tivoxavir marboxil could provide a valuable treatment option for patients at risk of bird flu.
• The company's progress could create opportunities for employees and attract new talent.

Next Steps

• Completion of the non-human primate challenge study.
• Discussion with the FDA regarding accelerated approval under the Animal Rule.
• Virtual Investor Update on March 31, 2025.
• Further development of tivoxavir marboxil as a one-time treatment for bird flu.

Key Dates